|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | CSD00256 |
| 保存条件 | store at -80℃ |
| 用途 | 仅用于科研用途 |
| 应用范围 | |
| 抗原来源 | CHO cells |
| CAS编号 | 934823-49-1 |
| 保质期 | 一年 |
| 抗体名 | Urelumab ( 乌瑞芦单抗 ) |
| 是否单克隆 | |
| 克隆性 | |
| 靶点 | TNFRSF9/CD137 [Homo sapiens] |
| 适应物种 | |
| 形态 | |
| 宿主 | |
| 标记物 | |
| 包装规格 | 1mg/ml |
| 纯度 | % |
| 亚型 | |
| 标识物 | |
| 浓度 | 95% |
| 免疫原 | |
| 是否进口 | 否 |
货号（Catalog No.）
CSD00256
通用名INN
Urelumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.
别名(Alternative names)
BMS-663513
靶点;物种(Specificity target name;species)
TNFRSF9/CD137 [Homo sapiens]
种类(Species)
Homo sapiens
受体鉴定(Receptor identification)
IgG4-kappa
化学信息
CAS：934823-49-1
存储条件(Storage)
store at -80°C
